Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BMO Capital Starts Eli Lilly at Outperform With $311 Price Target

11/19/2021 | 05:55am EST


ę MT Newswires 2021
All news about ELI LILLY AND COMPANY
01/21Innovent and Eli Lilly and Company Announces Final Clinical Results and Biomarker Analy..
CI
01/21GSK, Vir ramping up U.S. output of COVID antibody drug
RE
01/21Alzheimer's patient groups protest U.S. Medicare coverage proposal limiting use of new ..
RE
01/21DZ Bank Upgrades Eli Lilly and Co. to Buy From Hold; Price Target is $291
MT
01/20Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial..
PR
01/19Iterative Scopes, Inc announced that it has received $150 million in funding from Insig..
CI
01/18Evotec, Eli Lilly to Collaborate on Treatments for Metabolic Diseases
MT
01/18Evotec, Eli Lilly to Address Kidney Diseases, Diabetes in Three-Year Drug Discovery Col..
MT
01/18Eli Lilly, Evotec Team Up to Discover Drugs For Metabolic Diseases
MT
01/18Evotec SE Enters into a Drug Discovery Collaboration with Eli Lilly and Company
CI
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 27 946 M - -
Net income 2021 6 022 M - -
Net Debt 2021 11 909 M - -
P/E ratio 2021 37,8x
Yield 2021 1,37%
Capitalization 220 B 220 B -
EV / Sales 2021 8,31x
EV / Sales 2022 8,19x
Nbr of Employees 35 000
Free-Float -
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 243,06 $
Average target price 284,18 $
Spread / Average Target 16,9%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY-11.98%220 356
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
NOVO NORDISK A/S-14.11%219 146